A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)
Status
Active (Non-Recruiting)
Disease
Hepatocellular Carcinoma
Treament Agent
Tremelimumab + Durvalumab + Lenvatinib + TACE vs Tremelimumab + Durvalumab + TACE vs TACE
Study Phase
III
Resources and Links
Physician Name(s)
Dr John Low Seng Hooi
Dr Mastura Md Yusof
Description
Assessing the efficacy and safety of Durvalumab + Tremelimumab + TACE with or without Lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation)
Cancer Type
Liver Cancer
I would like to be a part of tomorrow's breakthrough
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you:
8, Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
.webp?sfvrsn=20763f7d_21)
.webp?sfvrsn=f2a2c343_12)
